Certain Common Stock of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 4-JAN-2018.
January 04, 2018
Share
Certain Common Stock of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 4-JAN-2018. These Common Stock will be under lockup for 30 days starting from 5-DEC-2017 to 4-JAN-2018.
Details:
Each of the executive directors and officers, and certain holders of common stock have agreed that, without the prior written consent of Morgan Stanley & Co. LLC, they will not, subject to limited exceptions, during the period ending 30 days after the date of this prospectus supplement, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by them or any other securities so owned convertible into or exercisable or exchangeable for common stock
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
EDITAS MEDICINE, INC. 
